“…Up to now, it was also reported that so many compounds such as hydroxyl and phenolic compounds, tetra-pyridine-triazole-substituted phthalocyanines, some uracil derivatives, acridine bissulfonamides, 1,3-bis-chalcone derivatives, pyrazole derivatives, 5-methyl-2,4-dihydro-3H-1,2,4triazole-3-one's aryl Schiff base derivatives, ureido benzenesulfonamides, chalcone substituted benzenesulfonamides, chalcones derivatives bearing morpholine moiety, Schiff bases of sulfa drugs, and alicilaldehyde-N-methylp-toluenesulfonylhydrazone were inhibited hCAs (Alyar and Adem, 2014;Esirden et al, 2015;Arslan et al, 2016;Salmas et al, 2016;Turkoglu et al, 2017;Alyar et al, 2018;Kursun Aktar et al, 2018;Lolak et al, 2019;Ozil et al, 2019;Turkan et al, 2019;Tutar et al, 2019;Arslan et al, 2020). Common CAIs such as acetazolamide (AAZ), celecoxib (CLX), ethoxzolamide (EZA), and methazolamide (MZA) have been reported as useful drugs in the treatment of many diseases such as glaucoma, edema, osteoporosis, idiopathic intracranial hypertension (Ahlskog et al, 2009).…”